Enzolytics, Inc. (ENZC)
OTCMKTS
· Delayed Price · Currency is USD
0.0007
+0.0001 (16.67%)
Apr 23, 2025, 3:01 PM EDT
Enzolytics Revenue
Enzolytics had revenue of $46.59K in the twelve months ending March 31, 2012, up 26.03% year-over-year. In the year 2011, Enzolytics had annual revenue of $52.81K with 42.85% growth.
Revenue (ttm)
46.59K
Revenue Growth
+26.03%
P/S Ratio
62.22
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2011 | 52.81K | 15.84K | 42.85% |
| Dec 31, 2010 | 36.97K | 22.26K | 151.35% |
| Dec 31, 2009 | 14.71K | 9.02K | 158.62% |
| Dec 31, 2008 | 5.69K | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SS Innovations International | 20.65M |
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Northwest Biotherapeutics | 1.38M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Enzolytics News
- 7 months ago - Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator - Accesswire
- 8 months ago - Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement - Accesswire
- 8 months ago - Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells - Accesswire
- 9 months ago - Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications - Accesswire
- 9 months ago - Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd. - Accesswire
- 9 months ago - Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release - Accesswire
- 10 months ago - Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment - Accesswire
- 11 months ago - Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology - Accesswire